In the original version of this article (1), the stated disclosure of José Baselga is incorrect. The error has been corrected in the latest online HTML and PDF versions of the article. The authors regret this error.
References
1.
Saura
C
, Roda
D
, Rosello
S
, Oliveira
M
, Macarulla
T
, Perez-Fidalgo
JA
, et al A first-in-human phase I study of the ATP-competitive AKT inhibitor ipatasertib demonstrates robust and safe targeting of AKT in patients with solid tumors
. Cancer Discov
2017
;7
:102
–13
.©2018 American Association for Cancer Research.
2018
American Association for Cancer Research.
RSS Feeds